In addition, the agreements fully resolve disputes and ongoing litigation between Beckman Coulter and Quidel.īeckman Coulter will supply Access BNP globally through the company's distribution channels and will partner with Quidel to transition customers, globally, to Access BNP over the coming months. Under the terms of the agreements, Quidel will continue to manufacture and supply certain components to Beckman Coulter related to the assay, and Beckman Coulter will exclusively manufacture and sell to customers the BNP assay currently sold as TRIAGE® BNP by Quidel, under the brand name Access BNP. Customers will benefit as the transaction will allow them to purchase all their testing needs from Beckman CoulterīREA, Calif., J/PRNewswire/ - Beckman Coulter, a global clinical diagnostics leader, today announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers. Laboratories will have continued supply of the high-quality BNP assay that exclusively runs on Beckman Coulter immunoassay platforms
This BNP assay for Beckman Coulter immunoassay analyzers, currently sold as TRIAGE® BNP by Quidel, will now be sold by Beckman Coulter under the brand name Access BNP Beckman Coulter to take over distribution to customers of a B-type Natriuretic Peptide (BNP) assay, a marker of congestive heart failure on the company's immunoassay platforms
0 kommentar(er)
